Eton Pharmaceuticals (NASDAQ:ETON) Releases Earnings Results, Hits Estimates

Eton Pharmaceuticals (NASDAQ:ETON) released its earnings results on Tuesday. The company reported ($0.02) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.02), Zacks reports. The firm had revenue of $11.65 million during the quarter, compared to the consensus estimate of $10.53 million. Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%.

Eton Pharmaceuticals Price Performance

NASDAQ ETON opened at $14.88 on Thursday. Eton Pharmaceuticals has a 1 year low of $3.03 and a 1 year high of $18.41. The stock has a market capitalization of $387.64 million, a PE ratio of -67.64 and a beta of 1.37. The company’s 50 day simple moving average is $15.51 and its two-hundred day simple moving average is $11.45.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $33.00 price objective on shares of Eton Pharmaceuticals in a report on Wednesday. Craig Hallum raised their price objective on shares of Eton Pharmaceuticals from $23.00 to $26.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, B. Riley reaffirmed a “buy” rating and issued a $24.00 price objective (up from $21.00) on shares of Eton Pharmaceuticals in a report on Wednesday.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.